{"created":"2023-05-15T16:49:25.003723+00:00","id":26864,"links":{},"metadata":{"_buckets":{"deposit":"daa8d056-8ab6-46e9-9303-ca36f9120f7d"},"_deposit":{"created_by":6,"id":"26864","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26864"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026864","sets":["8:9"]},"author_link":["119260","119249","119258","119254","119255","119244","119243","119259","119246","119247","119257","119242","119248","119250","119261","119262","119251","119264","119265","119263","119241","119253","119245","119256","119252"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-07-23","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"197","bibliographicVolumeNumber":"23","bibliographic_titles":[{"bibliographic_title":"Arthritis Research & Therapy"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective: To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world setting.\nMethods: A total of 242 patients with RA who were treated with tofacitinib (n = 161) or baricitinib (n = 81) were enrolled. We evaluated efficacy and safety between tofacitinib and baricitinib using multivariable analyses to avoid confounding. Their clinical disease activity and AEs were evaluated for 24 weeks.\nResults: The mean (SD) DAS28-ESR change from baseline to 24 weeks was 1.57 (1.55) (tofacitinib) and 1.46 (1.36) (baricitinib). There was no significant difference in the clinical response between the two groups (adjusted mean difference, 0.04; 95% CI, −0.35 to 0.28). The efficacy was not significantly changed in the patients without concomitant MTX use in both groups, but the concomitant MTX use showed better clinical efficacy in the cases of baricitinib treatment. In both groups, the most common AE was herpes zoster infection, and the AE rates were similar between the two groups. However, the predictive factors contributing to clinical response as revealed by a multivariable logistic analysis differed. The concomitant oral steroid use was independently associated with the achievement of DAS-low disease activity in the tofacitinib group, whereas in the baricitinib group, the number of biological and/or targeted synthetic DMARDs previously used was associated.\nConclusions: Our findings indicate that tofacitinib and baricitinib had comparable continuing efficacies and safety profiles. However, there is a possibility that the influence of clinical characteristics on the treatment response differs. The comparison provides useful information to the optimal use of JAK inhibitors in real-world settings.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Arthritis Research and Therapy, 23, art. no. 197; 2021","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BioMed Central Ltd"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/s13075-021-02582-z","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1478-6362","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Iwamoto, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sato, Shuntaro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kurushima, Shota"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Michitsuji, Toru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishihata, Shinya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okamoto, Momoko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsuji, Yoshika"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Endo, Yushiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimizu, Toshimasa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sumiyoshi, Remi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suzuki, Takahisa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okada, Akitomo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koga, Tomohiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawashiri, Shin-ya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fujikawa, Keita"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Igawa, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Aramaki, Toshiyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichinose, Kunihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tamai, Mami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Hideki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mizokami, Akinari"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Origuchi, Tomoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ueki, Yukitaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Eguchi, Katsumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-16"}],"displaytype":"detail","filename":"ART23_197.pdf","filesize":[{"value":"676.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ART23_197.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/26864/files/ART23_197.pdf"},"version_id":"5b0c1ff3-40b7-4d70-9ff3-47b298d3c580"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Rheumatoid arthritis","subitem_subject_scheme":"Other"},{"subitem_subject":"Tofacitinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Baricitinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Comparison","subitem_subject_scheme":"Other"},{"subitem_subject":"Molecular-targeted therapy","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis"}]},"item_type_id":"2","owner":"6","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-16"},"publish_date":"2021-11-16","publish_status":"0","recid":"26864","relation_version_is_last":true,"title":["Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T20:08:44.317131+00:00"}